COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
List view / Grid view
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans...
29 March 2016 | By Victoria White
Inovio has updated its clinical strategy to take its INO-3112 HPV immunotherapy into human studies in combination with selected molecules from MedImmune...
22 March 2016 | By Victoria White
Inovio’s DNA vaccine and dMAb products show potential to offer immediate and long term protection to large populations from CHIKV infection...
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
14 March 2016 | By Victoria White
Dr Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX later became Inovio Pharmaceuticals...
17 February 2016 | By Victoria White
In preclinical studies, Inovio's Zika DNA vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood...
19 November 2015 | By Victoria White
GeneOne Life Science and Inovio are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year...
19 October 2015 | By Victoria White
Earlier this year, Inovio’s MERS vaccine induced 100% protection from a live virus challenge in a preclinical study...
21 September 2015 | By Victoria White
DARPA is to provide the additional $24 million after Inovio successfully completed certain preclinical and clinical development milestones relating to the Ebola treatment programme...
30 July 2015 | By Victoria White
Inovio’s DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice...
3 June 2015 | By Victoria White
Inovio has said it will advance its DNA vaccine for MERS into a Phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science...